Ardelyx Inc (ARDX NASDAQ) stock market data APIs
$7.2539
-0.14(-1.9%)
as of February 6, 2026
Try our APIs with
free plan!
Ardelyx Inc Financial Data Overview
Price chart is built with
Anychart
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Prev. Close
7.2539
Open
7.111
High
7.287
Low
6.9261
52 wk Range
3.21-8.4
Market Cap
1 701 M
Shares Outstanding
243 M
Revenue
398 M
EPS
-0.004
Beta
0.578
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Ardelyx Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Ardelyx Inc data using free add-ons & libraries
Get Ardelyx Inc Fundamental Data
Ardelyx Inc Fundamental data includes:
- Net Revenue: 398 M
- EBITDA: -35 298 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-30
- EPS/Forecast: -0.0569
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Ardelyx Inc News
New
Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026
WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class m...
Ardelyx receives new patent for Tenapanor
Ardelyx (ARDX) announced that the United States Patent and Trademark Office, USPTO, has issued U.S. Patent No. 12,539,299 titled “Oral Formulations of Tenapanor” with an expiration date of Novembe...
Ardelyx, Inc. (ARDX) Gains TD Analysts Support Ahead of Q4 Results
We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Ardelyx, Inc. is next on our list. TheFly reported on January 29 that TD Cowen raised its price target on ARDX to $1...
Jefferies Remains a Buy on Ardelyx (ARDX)
Ardelyx, Inc. (NASDAQ:ARDX) is one of the Best Small Cap Stocks Ready to Explode in 2026. On January 27, Dennis Ding from Jefferies reiterated a Buy rating on the stock and raised the price target ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
